Sanofi Shines in Q3 2024 with Strong Growth and Innovation
SHERIDAN, WYOMING – November 08, 2024 – Sanofi, a leading global biopharmaceutical company, has announced outstanding results for the third quarter of 2024, showcasing robust financial performance and significant progress in its innovative product pipeline. The company's dedication to providing healthcare solutions for patients worldwide is reflected in its impressive double-digit sales growth and groundbreaking achievements in research and development.
Sanofi's Q3 2024 sales surged by 15.7% at constant exchange rates (CER), reaching €13,438 million. Business earnings per share (EPS) also saw a significant increase, rising by 12.2% on a reported basis and 17.6% at CER to reach €2.86. This strong performance was fueled by better-than-expected vaccine sales, particularly for influenza and Beyfortus (RSV), and the continued strong growth of Dupixent, the company's leading immunology drug.